固有のアデノシンがベータ・アドレノ受容体媒介のイノトロピック反応を阻害し,犬の心筋が過剰に充満している状態で反応する
1First Department of Medicine, School of Medicine, Osaka University, Japan.
Circulation
|April 1, 1992
まとめ
心筋力衰え中に放出される内生性アデノシンは,ベータアドレネルジック刺激に対する心臓の収縮反応を著しく鈍化させます. アデノシン放出を遮断すると,この反応が強化され,不血症状態におけるアデノシンの抑制作用が確認される.
科学分野:
- 心臓病学 心臓病学
- 心血管生理学 心血管の生理学
- バイオケミストリー バイオケミストリー
背景:
- アデノシンは,GTP結合タンパク質を介して,β-アドレノ受容体媒介反応をインビトロで弱くすることが知られている.
- この研究では,心筋不全の心臓組織から放出される内生性アデノシンが果たす役割を調査しています.
研究 の 目的:
- 缺血性心筋から放出されたアデノシンがベータ・アドレナージック刺激に対するイノトロピー反応を減少させるという仮説を検証する.
- アデノシンが,イシュケミア中の心臓の収縮性に影響するメカニズムを解明する.
主な方法:
- 誘発性心筋血を誘導したオープンチェストの犬モデルを使用しました.
- イソプロテレノールに対する評価されたイノトロピック反応は,心筋の断片縮小を測定することによって測定された.
- プラゾシンとアデノシン受容体アンタゴニスト8-フェニルテオフィリンを用いたアデノシン放出の操作.
主要な成果:
- 心筋低血流は,断片的縮小と乳酸抽出を減少させ,冠動脈静脈アデノシンレベルを上昇させた.
- イソプロテレノールの投与により,分数の縮小が強化されましたが,アデノシン放出が弱まった場合,この効果は著しく増加しました.
- 外因的なアデノシン投与とアデノシン受容体の対抗性により,アデノシンがイノトロピー反応に及ぼす抑制効果が確認されました.
結論:
- 缺血性心筋膜から放出された内生アデノシンは,β-アドレノ受容体媒介のイノトロプ反応を弱める.
- この衰弱は,交感性神経末端からのノレピネフリン放出とは無関係です.
関連する概念動画
Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...


